Target intelligence / Profile preview

Immunoglobulin superfamily member 21 (IGSF21)

Target
IGSF21
Molecular classification
Immunoglobulin superfamily, Synaptic adhesion molecule, GPI-anchored membrane protein
01

Overview

Immunoglobulin superfamily member 21 (IGSF21) is a GPI-anchored membrane protein containing two (or three, depending on isoform) immunoglobulin-like domains and is part of the immunoglobulin superfamily. It is specifically expressed in the brain on the postsynaptic membrane and acts as a synaptic adhesion molecule that interacts with presynaptic neurexin2α, facilitating the selective differentiation and organization of inhibitory (GABAergic) synapses, especially in the hippocampus and cortex. Knockout mouse studies show that IGSF21 is essential for proper inhibitory synaptic transmission and that its absence leads to deficits in CNS inhibitory networks and sensorimotor gating. IGSF21 is not currently associated with any therapeutic drugs or direct biomarker applications, but its biological role makes it relevant to the fundamental understanding of inhibitory synapse regulation in the central nervous system.

Other names
Immunoglobulin superfamily member 21IGSF21IgSF21MGC15730RP11-121A23.1
02

Mechanism of action

Not applicable; there are no drugs or small molecules reported to modulate IGSF21, so no drug mechanisms of action are described.

03

Biological functions

Selective promotion of inhibitory presynaptic differentiation (GABAergic synapse development)Postsynaptic organizer interacting with presynaptic neurexin2α (NRXN2α) in the brainRegulation of synaptic inhibition via NRXN2α-mediated signaling
04

Disease associations

Neuropsychiatric and neurodevelopmental processes (mice lacking IgSF21 show sensorimotor gating deficits, indicative of potential links to psychiatric/neurodevelopmental disorders)Other (No established direct disease roles yet, but impairment affects inhibitory synaptic transmission and CNS function)
05

Safety considerations

No clinical safety concerns described; the protein is not a current therapeutic target.Knockout in mouse model affects inhibitory synapse formation and sensorimotor gating, which suggests potential adverse effects if targeted in human CNS

Beyond the preview

Go deeper on Immunoglobulin superfamily member 21 (IGSF21).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin superfamily member 21 (IGSF21).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call